Member, Human Biology and Public Health Sciences Division
Associate Director for Education and Career Enhancement
Endowed Chair of Graduate Studies
Affiliate Professor, University of Washington
Director, Office of Education and Training, Fred Hutch/UW Cancer Consortium
Director, Viral Pathogenesis and Evolution Training Program
My major project involves using CRISPR-Cas9 technology to define the dominant effectors of the type-I interferon response against HIV-1 in primary target CD4+T cells. I have also been involved in projects involving the type I interferon response against ZIKA virus and chimeric SIV/HIV viruses (SHIVs).
I am interested in identifying immune correlates of susceptibility to superinfection. I am also working on developing new approaches to comprehensive epitope mapping of monoclonal antibodies and plasma responses.
I study the evolution of human antibody responses directed against HIV-1 infection. We sequence antibody genes from B cells within longitudinal patient blood samples to estimate how their HIV-specific antibody lineages developed.
I am interested in defining which interferon-stimulated genes are involved in the restriction of lentiviruses.
I am currently working on isolating and characterizing HIV-specific broadly neutralizing antibodies from women who are superinfected with HIV-1. Superinfection with two distinct viral strains generates a broad polyclonal repertoire of neutralizing antibodies targeted to HIV. Understanding how these antibodies evolve and develop may assist future vaccine design.
I am interested in studying the function and epitope of antibodies that potentially mediate protection from HIV, with the goal of informing HIV vaccine design.
I am examining Zika virus as a cause of fever in Kenya and studying the role of type-I interferon in restricting Zika virus replication.
I am interested in applying high-throughput techniques to identify interferon-induced genes that are potent inhibitors of early viral infection and replication (restriction factors).
I am interested in studying the evolution of both neutralizing and non-neutralizing antibodies in HIV-1 infected individuals. I would also like to better understand how effector functions influence whether a given antibody will be beneficial or detrimental in the context of HIV infection.
I am interested in the characterization of viral diversity and evolution in HIV infected infants as well as the ability to quantify the HIV-1 latent reservoir with novel ddPCR methods.
I perform Gen Probe QC HIV viral RNA loads and population based sequencing for resistant mutations for women on ARV for the QRS cohort. I’ve also been involved with neutralization assays using the PBMC and TZM methods for PBMC and 293T-passaged chimeras with monoclonal antibodies.
I am studying the evolution of antibodies that mediate antibody-dependent cellular cytotoxicity; I am focused specifically on characterizing gp120-directed antibodies.
I am interested in studying the diversity and evolution of HIV-1 in Kenyan infants to understand the timing of infection.
Currently, I'm involved in projects designed to study the interface between Zika virus and type-I interferon, a critical component of the innate immune response. Additionally, I'm interested in characterizing Zika virus presence in eastern Africa and its contribution to febrile illness.
I've been a member of Julie's lab since 1993; first as an undergraduate then as a tech. I've been involved in a number of different projects over the years, most pertaining to cloning and characterizing HIV-1 envelopes. I'm also currently working on cloning HIV-1 specific antibodies.
I’m interested in exploring viral diversity and evolution in HIV-1 infected Kenyan infants and how it relates to antibody breadth.